12 citations
,
March 2016 in “Experimental Dermatology” This review discusses the potential for hand preference and sexual orientation to predict sexual side effects of finasteride in men with androgenic alopecia, but reports no new clinical results.
42 citations
,
December 2015 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.
5 citations
,
November 2015 in “Journal of Mind and Medical Sciences” This review discusses the adverse effects of finasteride for male androgenic alopecia, highlighting depressive symptoms and persistent sexual dysfunction, and reports no new clinical findings.
29 citations
,
September 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.
50 citations
,
July 2014 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.
81 citations
,
June 2014 in “American Journal of Men's Health” This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
19 citations
,
November 2012 in “BJUI” In this study, researchers observed that the sexual effects of dihydrotestosterone deprivation using finasteride may vary by handedness, with right-handed men often experiencing lower sexual function and left-handed men showing no effect or improvement.
134 citations
,
August 2012 in “The Journal of Clinical Psychiatry” This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.
6 citations
,
August 2012 in “PubMed” In this report, a 44-year-old woman with female pattern alopecia experienced significant hair regrowth after 3.5 months of oral finasteride, with no side effects, after not responding to topical minoxidil.
112 citations
,
July 2012 in “The Journal of Sexual Medicine” In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.
35 citations
,
February 2012 in “Journal of The American Academy of Dermatology” This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.
29 citations
,
January 2009 in “International Journal of Trichology” This report describes two cases of gynecomastia linked to the use of Finasteride (Propecia®) for treating androgenetic alopecia, highlighting a rare but important side effect.
225 citations
,
July 2007 in “The Journal of Sexual Medicine” In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.
7 citations
,
April 2007 in “PubMed” This case report describes a novel occurrence of erythema annulare centrifugum associated with finasteride use for androgenetic alopecia, which resolved upon discontinuation and recurred with reintroduction.
8 citations
,
October 2002 in “Journal Of Clinical Periodontology” This study suggests that levamisole and finasteride can significantly reduce DHT levels in human gingival fibroblasts, potentially addressing phenytoin-induced gingival overgrowth.
123 citations
,
December 1997 in “Calcified Tissue International” This study concluded that higher androgen levels in males and specific skeletal sites may contribute to differences in skeletal morphology, with glucocorticoids, E2, and D3 enhancing androgen receptor expression and mitogenic action in human osteoblastic cells.
93 citations
,
January 1996 in “Clinical Pharmacokinectics” Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
70 citations
,
August 1995 in “Fertility and Sterility” In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.
34 citations
,
July 1993 in “PubMed” This article reviews the characteristics and uses of finasteride for benign prostatic hyperplasia, noting variable symptom improvement and ongoing investigation in other DHT-mediated conditions, and reports no new clinical results.
